TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Invex Therapeutics Ltd. ( (AU:IXC) ) has shared an update.
Invex Therapeutics Limited has requested an extension to its voluntary suspension of trading on the ASX, initially commenced on September 25, 2025. This extension is sought pending an important announcement and response to a price query from the ASX, with trading expected to resume by September 30, 2025. The company has indicated no known reasons against granting the suspension, suggesting it is a strategic move to manage market expectations and regulatory compliance.
More about Invex Therapeutics Ltd.
Invex Therapeutics Limited operates in the biotechnology industry, focusing on developing innovative therapeutic solutions. The company is primarily engaged in the research and development of treatments for neurological conditions, with a particular emphasis on addressing unmet medical needs in this sector.
Average Trading Volume: 69,125
Technical Sentiment Signal: Buy
Current Market Cap: A$12.02M
For an in-depth examination of IXC stock, go to TipRanks’ Overview page.